TRB Chemedica International

OUR HISTORY

Read about the key events during our three decades of success

TRB VOUVRY

Learn more about our Swiss production site

PARTNERSHIPS

Partnerships have been the key to our worldwide development, join our network

SWISS FIRM, GLOBAL NETWORK

Our strong network of 19 subsidiaries and distribution partners helps us to support patients and healthcare professionals in over 70 countries around the world.

See our locations

We care

From easing the discomfort of dry eye to aiding recovery following arthroscopy, through helping relieve pain and compromised function which results from tendinopathy or osteoarthritis, everything we do is because we care.

Our focus areas

We develop and manufacture highly effective pharmaceutical products, medical devices, and medical food supplements, all with excellent safety profiles.

HYALURONIC ACID DIACEREIN GM1 ganglioside

NEWSROOM

Catch up with the latest news, articles, events, and videos from TRB Chemedica International

TRB AT A GLANCE

TRB WORLDWIDE

HISTORY

OPHTHALMOLOGY

RHEUMATOLOGY

NEUROLOGY

HYALURONIC ACID

DIACEREIN

GM1 GANGLIOSIDE

TRB CHEMEDICA VOUVRY

SCIENTIFIC COOPERATION

IN-LICENSING

OUT-LICENSING

New publication of a large French clinical trial evaluating Ostenil Plus in osteoarthritis

TRB and KiOmed Pharma conclude a license and supply agreement to commercialise innovative osteoarthritis treatment

We are very proud to unveil our new brand identity

OUR HISTORY

TRB VOUVRY

PARTNERSHIPS

SWISS FIRM, GLOBAL NETWORK

We care

NEWSROOM

New publication of a large French clinical trial evaluating Ostenil Plus in osteoarthritis

OUR HISTORY

TRB VOUVRY

PARTNERSHIPS

SWISS FIRM, GLOBAL NETWORK

OPHTHALMOLOGY

RHEUMATOLOGY

NEUROLOGY

Our focus areas

We are very proud to unveil our new brand identity

New publication of a large French clinical trial evaluating Ostenil Plus in osteoarthritis

TRB and KiOmed Pharma conclude an agreement to commercialise innovative OA treatment